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Purpose: To correlate polymorphisms in genes involved in the
transport, activation, and inactivation of pemetrexed with the out-
come of patients with advanced non-small cell lung cancer
(NSCLC) treated with pemetrexed.
Experimental Design: Data from a phase II NSCLC trial evaluating
the optimal schedule of gemcitabine and pemetrexed were used. All
patients with available DNA were genotyped for polymorphisms in
FPGS, GGH, and SLC19A1 genes. Patients with various genotypes
were compared for efficacy and adverse events resulting from
pemetrexed.
Results: Fifty-four patients had genotype results for all polymor-
phisms studied. Patients with the homozygous variant genotypes for
SLC19A1 IVS4(2117) CT, IVS5(9148) CA, and wild-type ge-
notype for exon6(2522) CT had a significantly better overall
survival compared with their counterparts (median overall survival
in months: 8.9 [CC] versus 14.0 [CT] versus 16.7 [TT]; 9.4 [CC]
versus 10.3 [CA] versus 22.7 [AA]; and 22.7 [CC] versus 10.3 [CT]
versus 9.4 [TT] respectively; all log rank p 0.03). Patients with the
heterozygous TC genotype for GGH IVS5(1042) TC had greater
rates of confirmed response  stable disease compared with the TT
genotype (85% versus 60%; odds ratio  4.0; p  0.06). A greater
risk for grade 3/4 SGPT (ALT) elevation was observed in patients
heterozygous (GA) for the FPGS IVS1 (28) GA polymorphism
compared with the GG genotype (43% versus 13%; odds ratio 
5.0, p  0.07). All results were largely consistent within patients
with nonsquamous (n  40) histology.
Conclusion: Polymorphisms in SLC1A91 seem to predict for sur-
vival differences in pemetrexed-treated NSCLC. Additionally, poly-
morphisms in GGH and FPGS have marginal associations with
response and adverse event. These results should be validated in
larger prospective studies using pemetrexed.
Key Words: Polymorphisms, Reduced folate carrier gene,
SLC19A1, Pemetrexed, Non-small cell lung cancer.
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The potency of pemetrexed, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-day]pyrimidin-5-yl)-ethyl]-benzoyl]-
L-glutamic acid, compared with numerous other classic antifo-
lates including methotrexate is due to pemetrexed’s rapid
transport into cells by the reduced folate carrier protein, RFC,
encoded by the gene SLC19A1. Pemetrexed is transported
into cells about two times faster than methotrexate1,2 and
binds to the folate receptor- with a very high affinity, similar
to that of folic acid.3 Pemetrexed has been shown to be one of
the best substrates for folylpolyglutamate synthetase protein
encoded by FPGS, when compared with numerous other
classic antifolates.4 Once it enters cells, pemetrexed is poly-
glutamated to the active pentaglutamate. Steady-state accu-
mulation of pemetrexed polyglutamates depends primarily on
activation/inactivation processes by FPGS and gamma glu-
tamyl hydrolase encoded by GGH. The pentaglutamate form
of pemetrexed is the predominant intracellular form and is
60-fold more potent in its inhibition of thymidylate
synthase the target protein, than the monoglutamate.5 Poly-
glutamation traps pemetrexed and enhances its intracellu-
lar retention. This polyglutamation competes with the
hydrolysis of the accumulated pentaglutamate tails cata-
lyzed by the GGH enzyme, thus allowing the efflux of
pemetrexed out of the cells.6
Pemetrexed inhibits multiple folate-dependent enzyme
targets most notably thymidylate synthase, resulting in de-
creased thymidine necessary for DNA synthesis.7–9 It also
inhibits dihydrofolate reductase and glycinamide ribonucle-
otide formyltransferase.5
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Pemetrexed was first approved for second-line treat-
ment of non-small cell lung cancer (NSCLC) in 2005.10 It has
also shown activity in a variety of solid tumors such as
colorectal, gastric, breast, cervical and bladder cancers, in
combination with other chemotherapeutic agents.11 In the
past year, pemetrexed has been approved for the first-line
therapy for nonsquamous NSCLC.12,13
The molecular mechanism underlying the resistance to
pemetrexed6,14–18 may in part be due to alterations in the
genes encoding the FPGS, GGH, and SLC19A1 proteins,
which are responsible for the transport, activation, and inac-
tivation of pemetrexed. These alterations might result in
variations in clinical response and/or toxicity. Therefore,
several or all these enzymes may play a part in determining
the effectiveness of pemetrexed therapy in patients with
NSCLC.
Based on the above, we focused on genetic variations
that might affect the genes transporting, activating, and inac-
tivating pemetrexed. We hypothesized that germ-line single-
nucleotide polymorphisms (SNPs) in SLC19A1(transport),
FPGS (activation), and GGH (inactivation), either singly or
in combination, may play a role in the efficacy and/or toxicity
of pemetrexed. Thus, we examined the association between
tag SNPs of FPGS, GGH, and SLC19A1 and outcomes in
patients who received pemetrexed on a North Central Cancer
Treatment Group phase II NSCLC trial.19
PATIENTS AND METHODS
Patients and Study Design
A randomized three-arm phase II study was undertaken
to evaluate the optimal administration schedule of pem-
etrexed and gemcitabine in chemo-naive patients with
NSCLC.19 Briefly, patients were enrolled into one of the
following three schedules: (a) pemetrexed followed 90 min-
utes later by gemcitabine on day 1 and gemcitabine on day 8;
(b) gemcitabine followed 90 minutes later by pemetrexed on
day 1 and gemcitabine on day 8; or (c) gemcitabine on day 1
and pemetrexed followed 90 minutes later by gemcitabine on
day 8. Patients provided written informed consent, and the
study protocol was approved by each participating site’s
institutional review board. A total of 152 patients from the
three schedules (A: 59, B: 31, and C: 62) were evaluable, and
the results of the primary endpoint have been previously
reported.19 Approximately 94% of the patients were of white
origin. No statistically significant differences were observed
among the three treatment schedules in the distribution of
age, sex, race, or stage. Schedule A achieved a response rate
of 31% compared with 6.5% with schedule B and 16% with
C. Of these, only schedule A met the protocol-defined re-
sponse criteria for being worthy of further evaluation. Sched-
ule B was discontinued after interim analysis because of the
poor response rate. The median survival time (schedules A,
B, and C: 11.4, 10.3, and 11.8 months, respectively) and time
to disease progression (schedules A, B, and C: 4.7, 4.1, and
4.4 months, respectively) were similar among the three
schedules.
Selection of Tag SNPs
We used our previous resequencing data from the white
population to derive a combination of haplotype (ht)-tag and
linkage disequilibrium (LD)-tag SNPs for FPGS.20 We then
searched the HapMap white database and obtained polymor-
phism (SNP) information for GGH and SLC19A1. Specifi-
cally, we loaded the SNP genotype datasets for the genes into
Haploview, and polymorphisms with frequencies greater than
5% were selected for haplotype analysis at an r2 threshold 
0.8. Haplotypes close to or above 2% frequency were orga-
nized into single blocks from which the ht-SNPs were de-
rived. Tag SNPs were also generated from the same data
using the tagger software in Haploview v 4.1. SNPs that did
not overlap from either analysis were included in the list of
tag SNPs (Table 1) to provide a more complete coverage of
the genetic variability in these three genes. A total of 19 loci
were derived for genotyping.
DNA Extraction and Genotyping
Ten milliliters of blood was drawn into ethylenedia-
minetetraacetic acid (EDTA) tubes and shipped to the
North Central Cancer Treatment Group central laboratory,
where DNA was extracted and batched until the end of the
study for the genotyping assay described later.
DNA samples were available for 61 of 152 patients on
study because the protocol was amended to collect blood
specimens for pharmacogenetics part way through the study,
and participation in the translational component was optional.
Three patients with DNA samples available were ineligible
(central pathology review determined that patients had small
cell lung cancer), and four samples failed during genotyping.
Therefore, a total of 54 samples were successfully genotyped
for the 19 loci in FPGS, GGH, and SLC19A1.
Genotyping was performed using the MassARRAY
Compact system (Sequenom) in the Microarray and Genom-
ics Core Facility at Roswell Park Cancer Institute. All geno-
typing was polymerase chain reaction (PCR) based and was
performed using established methods at Roswell Park Cancer
Institute. The primary genotyping platform for SNP analysis
uses the Sequenom MassARRAY platform. This system uses
mass spectrometry in the detection and analysis of primer-
extended PCR products.21 All reactions were carried out in a
PTC225 thermal cycler (MJ Research, Inc.). DNA samples
selected from the Centre d’Etude du Polymorphisme Humain
(CEPH) reference families in addition to DNA samples from
the white population set from the Coriell Cell Repository
served as control samples for genotyping.
Statistical Analysis
Overall survival (OS) was defined as the time from
randomization to death from any cause. Progression-free
survival was defined as the time from randomization to the
earlier of disease progression or death from any cause. Ad-
verse events (AEs) were graded according to the National
Cancer Institute Common Toxicity Criteria (version 2). Con-
firmed response (CR) was defined as either a complete or
partial response (PR) per RECIST, observed on two consec-
utive evaluations at least 4 weeks apart. Fisher’s exact test
and logistic regression models adjusted for treatment arm
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were used to explore the differences in CR and AE rates
between the genotype variant subgroups. Kaplan-Meier sur-
vival curves,22 log-rank tests,23 and Cox proportional hazards
models adjusted for treatment arm were used to compare the
time to event distributions for the various genotype sub-
groups. In view of the fact that 17 of the 19 SNPs were
analyzed, p values 0.0003 would be deemed statistically
significant using the Bonferroni method for multiple compar-
isons. However, given the limited sample size of 54 patients,
and the various outcomes explored, all analyses were consid-
ered exploratory with no adjustments for multiple compari-
sons. Each SNP was explored by itself. Gene-gene interac-
tions and simultaneous exploration of more than one SNP
was not performed because of the sample size limitation.
RESULTS
Patient Characteristics
There were no significant differences in the baseline
characteristics of the 54 patients included in this analysis
compared with the rest of the 152 evaluable patients from
the trial. The median age was 65 years (range: 43–85).
Ninety-three percent of the patients had stage IV disease:
54% were men and 59% had a performance status of 1.
Fourteen (26%) of the 54 patients had squamous cell
histology. See Table 2 for details. These patient numbers
were too few for specific analyses. However, tumor his-
tology has been reported to be a determinant of pemetrexed
efficacy in NSCLC; therefore, analyses were performed
with and without the 14 squamous samples (nonsquamous
only), and the results remained consistent.
Genetic Polymorphisms: Tag SNPs and
Distribution of Variants
A total of 19 tag SNPs from the three genes FPGS,
GGH, and SLC19A1 were derived through LD and haplotype
analyses. Seventeen of the19 loci passed the genotyping
quality control test and two failed. Table 1 shows the SNP
identities and the genotype and minor allele frequencies
(MAFs) for the study samples. All the SNPs were in Hardy-
Weinberg equilibrium for the patient and control samples
used. Frequency distributions were similar between our study
samples and those reported in the HapMap database for white
samples. Except for FPGS IVS1(28)GA with MAF of
8.3%, all other SNPs included in the analyses had MAFs
10%. Genotypes of patient samples with variant distribu-
tion 7% (N 4) were excluded from the analysis with
clinical outcomes because of their low numbers. Also, anal-
ysis with squamous only samples were not performed be-
cause of the low number, N  14.
Genetic Polymorphisms and Survival
Differences in OS were observed in patients harboring
four SNPs in SLC19A1 namely IVS2(4935)GA,
IVS4(2117)CT, IVS5(9148)CA, and exon6(2522)CT.
Three of these SNPs, IVS4(2117)CT, IVS5(9148)CA,
and exon6(2522)CT, were significantly associated with OS,
log-rank p  0.03 (Table 3, Figures 1 and 2). For patients
TABLE 1. Distribution of Genotype and Allele Frequencies in Patients
id Gene
Gene
ID/Chromosomal
Location dbSNP id
SNP Location/
Genotype
Genotype (Frequency, %) (N  54) Minor Allele
Frequency (MAF),
Study SampleWild Type Heterozygous Variant
1 FPGS 2356/9q34.1 rs36204706 5FR (-747) C>T CC (98.2) CT (1.8) TT (0.0) 0.009
2 na 5FR (-573) CG CC (77.8) CG (20.4) GG (1.8) 0.120
3 na IVS1(28) GA GG (85.2) GA (13.0) AA (1.8) 0.083
4 rs41307463 IVS9(48) C>T CC (96.3) CT (3.7) TT (0.0) 0.019
5 GGH 8836/8q12.3 minus
strand nucleotides
shown for GGH
rs11545077c Exon1(91) CT
Ala31Thr
CC (51.9) CT (44.4) TT (3.7) 0.259
6 rs3780126 IVS1(1307) CT CC (33.3) CT (51.9) TT (14.8) 0.407
7 rs11990678 IVS2(2442) TC TT (79.6) TC (18.5) CC (1.9) 0.111
8 rs3780130 IVS3(1950) AT AA (63.0) AT (33.3) TT (3.7) 0.204
9 rs7010484 IVS5(1042) TC TT (55.6) TC (37.0) CC (7.4) 0.259
10 rs11995525 IVS7(1478) GA GG (48.2) GA (44.4) AA (7.4) 0.296
11 rs12677953 IVS7(6177) CA CC (75.9) CA (24.1) AA (0.0) 0.120
12 SLC19A1a 6573/21q22.3 rs914232 IVS2(4935) GA GG (37.0) GA (42.6) AA (20.4) 0.417
13 rs2838958 IVS4(2117) CT CC (22.2) CT (48.2) TT (29.6) 0.537
14 rs2297291 IVS5(391) CT CC (37.1) CT (44.4) TT (18.5) 0.407
15 rs2838956 IVS5(707) CT CC (16.7) CT (48.1) TT (35.2) 0.592
16b rs3788189 IVS5(9148) CA CC (22.2) CA (44.5) AA (33.3) 0.556
17b rs1051298 Exon6(2522) CT
(3’UTR)
CC (33.3) CT (44.5) TT (22.2) 0.444
Bold italicized items were not included in the correlations with clinical outcomes based on the distribution of the variants.
a Nucleotides shown for SLC19A1 are on plus strand.
b Frequency distribution of wild-type CC in IVS5(9148) is the same as for variant TT in Exon6(2522) and vice versa; CC  TT, CA  CT, AA  CC.
c Previously known as rs13270305.
N: number of patient samples; na: no dbSNP id available.
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with IVS4(2117)CT polymorphism, the OS for those with
the homozygous variant genotype TT was 16.7 months, the
heterozygous CT was 14 months, and the wild-type CC
genotype was 8.9 months, log-rank p 0.03 (Figure 1, Table
3). The frequency for the wild-type CC genotype in
IVS5(9148)CA polymorphism was 22.2%, same as that for
variant TT genotype in exon6(2522)CT. Similarly, fre-
quency for the variant AA genotype in IVS5(9148)CA was
33.3%, same as that for wild-type CC genotype in
exon6(2522)CT (Table 2). Thus, the nucleotide frequency
distribution at these two loci for the patients was similar. The
OS of the patients was similarly distributed for the genotypes.
Thus, patients with variant AA genotype in IVS5(9148)CA
and wild-type CC genotype in exon6(2522)CT had median
survival of 22.7 months compared with their counterparts
with heterozygous genotypes of 10.3 months and CC or TT
genotypes of 9.4 months, respectively, log-rank p  0.03
(Table 3, Figures 2A, B). All these results were consistent
after adjusting for treatment arm in Cox proportional hazards
models (Table 3). At a log-rank p  0.09, the association of
SLC19A1 IVS2(4935)GA polymorphism with OS in pa-
tients was marginal. Patients with GG genotype had a median
survival of 18.6 months, 10.6 months for those with the GA
genotype, and 9.3 months for the AA variant genotype (Table
3, Figure 3). After excluding the squamous cell patients
harboring these polymorphisms, the results in Table 3 re-
mained consistent with the exception of a significant associ-
ation for SLC19A1 IVS2(4935)GA polymorphism with OS,
a log-rank change from p  0.09 (N  54) to p  0.02 (N 
40) probably due to the fewer sample numbers. There was a
nonsignificant trend toward a more prolonged PFS for the
wild-type SLC19A1 exon6(2522) CC genotype; however, in
general, no difference in PFS was observed for the polymor-
phisms both overall and within the nonsquamous histology
patients.
Genetic Polymorphisms and AEs
Grade 3/4 AEs, regardless of attribution, were observed
in approximately 15% of the patients who had complete
genotype data. The common (occurring in 10% or more of
patients) grade 3/4 AEs included fatigue, observed in 20% of
the patients, neutropenia (69% of patients), leukopenia (50%
of patients), thrombocytopenia (15% of patients), dyspnea
(19% of patients), and SGPT (alanine aminotransferase
[ALT]) elevation (17% of patients). No statistically signifi-
cant association with AEs was observed for any of the SNPs
with the exception of a few trends noted below.
For FPGS, patients with the IVS1(28)GA polymor-
phism showed a high risk of grade 3/4 SGPT (ALT) (odds
ratio [OR] 5.0, p 0.07). Specifically, a higher percentage
of patients with heterozygous GA had elevated SPGT (43%)
than those homozygous for the wild-type genotype GG (13%)
(Fisher’s exact test p  0.09) (Table 3). Similar to FPGS,
GGH showed no difference in most of the severe AEs;
however, patients with the AT genotype for the
IVS3(1950)AT polymorphism had a lower risk for grade
3/4 fatigue (OR 0.1, p 0.08): the wild-type AA genotype
was associated more with fatigue than the AT genotype (29%
versus 6%; Fisher’s exact test p  0.07) (Table 3). Patients
with the GGH IVS2(2442)TC polymorphism showed a
significantly higher risk for grade 3/4 dyspnea (OR  7.3,
p  0.04): more patients with the TC genotype had grade 3
dyspnea compared with those with the TT genotype (40%
versus 14%; Fisher’s exact test p  0.08) (Table 3). The
results were consistent within the patients with nonsquamous
histology.
Genetic Polymorphisms and Tumor Response
No statistically significant association was observed for
any of the polymorphisms in FPGS, SLC19A1, and GGH
with CR and clinical benefit (CB) rates (defined as CR plus
stable disease), even when analysis were performed with only
nonsquamous histology samples. However, a trend toward a
higher CR and CB rates was seen in patients with the TC
heterozygous genotype compared with the TT genotype for
GGH IVS5(1042)TC (CR: 40% versus 17%, Fisher’s exact
test p  0.10; CB: 85% versus 60%, Fisher’s exact test p 
0.07). These results were consistent after adjusting for treat-
ment arm in logistic models, where patients with TC geno-
type were more likely to have a CR and CB (CR: TT versus
TC: OR  3.9, p  0.06; CB: TT versus TC: OR  4.0, p 
0.06) (Table 3). The discordance between polymorphisms
and association with CR and OS is unclear. It might be due to
the small sample size; however, in NSCLC, response rates do
not always correlate with OS.
TABLE 2. Baseline Characteristics
Characteristics
All Patients
(N  152)
Patients with
DNA
Genotyped
(N  54)
paN Percentage N Percentage
Age, median (range) 65 (39–85) 65 (43–85) 0.55b
Gender
Female 60 39.5 25 46.3 0.42
Male 92 60.5 29 53.7
Homocysteine
12 94 61.8 34 63.0 0.65
12 25 16.4 11 20.4
Unknown 33 21.7 9 16.7
Performance score
0 55 36.2 22 40.7 0.62
1 97 63.8 32 59.3
Dominant disease status
Soft tissue 31 20.4 9 16.7 0.60
Osseous 5 3.3 3 5.6
Visceral 116 76.3 42 77.8
Stage
IIIB 20 13.2 4 7.4 0.33
IV 132 86.8 50 92.6
Histology
Squamous 31 20.4 14 25.9 0.45
Nonsquamous 117 77.0 40 74.1
Missing 4 2.6 0 0.0
a Fisher’s exact test.
b Rank-Sum Test.
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DISCUSSION
Germ-line polymorphisms have been reported to have
major effects on efficacy and toxicity in patients undergoing
treatment with anticancer drugs such as erlotinib, gefitinib,
gemcitabine, cisplatin, taxanes, and platinum agents.24–27 In
this study, we evaluated the association of polymorphisms in
pemetrexed-related genes with outcomes from combination
therapy with gemcitabine. We realize that the overall toxicity
and efficacy profile of the treatment outcome might be influ-
enced by gemcitabine’s contribution to the therapy, but there
are studies that have evaluated single-drug (irinotecan or
5-fluorouracil)-related polymorphisms in combination thera-
pies where relevant polymorphisms have been found to cor-
relate with toxicity and treatment outcomes.28,29
This study was based on accumulating data suggesting
that resistance to antifolates, such as pemetrexed, may be due
in part to decreased SLC19A1 transport, increased GGH
expression or decreased FPGS expression, and/or inactivating
mutations,14–18 hence the molecular mechanism underlying
this resistance might be due to genetic variations in these
genes. Therefore, we focused our study on several tag SNPs
in the genes responsible for transporting (SLC19A1), activat-
ing (FPGS), and inactivating (GGH) pemetrexed. Very few
studies have examined the role of genetic polymorphisms in
pemetrexed therapy for NSCLC. Therefore, we used samples
from a randomized three-arm phase II study performed to
evaluate the optimal administration schedule of pemetrexed
and gemcitabine in chemo-naive patients with NSCLC19 to
TABLE 3. Genotype and Outcomes
Adverse Event Genotype Frequency (%) pa Odds Ratio (p)b
Grade 3 SGPT (ALT) FPGS IVS1(28) GA 0.09
GG 13 1.0 (—)
GA 43 5.0 (0.07)
Grade 3 fatigue GGH IVS3(1950) AT rs3780130 0.07
AA 29 1.0 (—)
AT 6 0.1 (0.08)
Grade 3 dyspnea GGH IVS2(2442) TC rs11990678 0.08
TT 14 1.0 (—)
TC 40 7.3 (0.04)
Response Genotype Frequency (%) pa Odds Ratio (p)b
Confirmed response GGH IVS5(1042) TC rs7010484 0.10
TT 17 1.0 (—)
TC 40 3.9 (0.06)
Clinical benefit (confirmed
response stable disease)
GGH IVS5(1042) TC rs7010484 0.07
TT 60 1.0 (—)
TC 85 4.0 (0.06)
Adverse Event Genotype Median (months) pc Hazard Ratio (p)d
Overall survival SLC19A1 IVS2(4935)GA rs914232 0.09
GG 18.6 1.0 (—)
GA 10.6 1.2 (0.71)
AA 9.3 2.3 (0.05)
SLC19A1 IVS4(2117)CT rs2838958 0.03
CC 8.9 1.0 (—)
CT 14.0 0.5 (0.04)
TT 16.7 0.4 (0.02)
SLC19A1 IVS5(9148)CA rs3788189 0.03
CC 9.4 1.0 (—)
CA 10.3 0.5 (0.08)
AA 22.7 0.3 (0.01)
SLC19A1 Exon6(2522)CT rs1051298 0.03
CC 22.7 1.0 (—)
CT 10.3 1.5 (0.27)
TT 9.4 3.0 (0.01)
a Fisher’s exact test.
b Logistic regression model adjusted for treatment arm. Frequency distribution of wild type CC in IVS5(9148) is the same as for variant TT in Exon6(2522) and vice versa; CC 
TT, CA  CT, AA  CC.
c Log-rank test.
d Cox proportional hazards model adjusted for treatment arm.
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evaluate potential associations between germ-line polymor-
phisms of SLC19A1, FPGS, and GGH and the efficacy and
toxicity of pemetrexed.
Three tag SNPs in SLC19A1 namely IVS4(2117)CT,
IVS5CA, and exon6(2522)CT were significantly associ-
ated with OS (p  0.03), whereas the fourth SNP,
IVS2(4935)GA showed a marginally significant association
(p  0.09). Patients with the variant AA genotype for
IVS5(9148) and those with wild-type CC genotype at
exon6(2522) had a significantly longer survival with a
median of 22.7 months than their counterparts with homozy-
gous and heterozygous genotypes (9.4 and 10.3 months,
respectively). Additionally, the variant genotype TT in
IVS4(2117)CT polymorphism predicted for improved OS.
Although there were no significant associations between any
of the polymorphisms and AEs or response, certain SNPs
FIGURE 1. Kaplan-Meier estimates for pa-
tients with non-small cell lung cancer
(NSCLC) undergoing pemetrexed and gem-
citabine combination therapy. Median over-
all survival (OS) was plotted by SLC19A1
IVS4(2117)CT polymorphism (rs2838958):
CC versus CT versus TT genotypes; CC: N 
12, number of events  12; CT: N  26,
number of events  21; and TT: N  16,
number of events  12.
FIGURE 2. Kaplan-Meier estimates for pa-
tients with non-small cell lung cancer
(NSCLC) undergoing pemetrexed and gem-
citabine combination therapy. A, Median
overall survival (OS) was plotted by
SLC19A1 IVS5(9148)CA polymorphism
(rs3788189): CC versus CA versus AA geno-
types; CC: N  12, number of events  12;
CA: N  24, number of events  19; and
AA: N  18, number of events  14. B,
Median OS was plotted by SLC19A1
exon6(2522)CT polymorphism
(rs1051298): CC versus CT versus TT geno-
types; CC: N  18, number of events  14;
CT: N  24, number of events  19; and
TT: N  12, number of events  12. Fre-
quency distributions of genotypes at loci
were equal.
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demonstrated a trend toward improved response rates (het-
erozygous TC genotype for GGH IVS2(1042) TC were
more likely to respond compared with those with the TT
genotype; OR p value  0.06) and elevation of transaminase
activity (presence of variant allele in FPGS IVS1(28)GA;
OR p value  0.07). These findings have to be interpreted
with caution given the approximately 100 comparisons ex-
plored in this study (17 SNPs and six different outcomes). At
a threshold of 5%, this means at least five of these 100
comparisons would likely have resulted in a significant find-
ing by chance alone. If the p values were adjusted for the
multiple comparisons, only p values less than 0.0005 would
be deemed statistically significant. Given that the p values
were on the order of 0.01 to 0.09, the “significant” and the
“marginally significant” findings from this analysis should be
viewed as promising.
In a recent study, the SLC19A1 exon6(2522)CC geno-
type correlated with longer median PFS and 3-month pro-
gression in patients undergoing pemetrexed-bevacizumab
combination therapy.30 In this study, it predicted for OS, p 
0.03. This exon6(2522)CT polymorphism is in LD with
SLC19A1 SNP rs1051266, an exon2(80)GA (R27H) poly-
morphism (D’ 0.963, r2 0.837, log of the likelihood odds
ratio (LOD)  24.42), whose homozygous AA variant geno-
type has been associated with worse outcome in children with
acute lymphoblastic leukemia treated with methotrexate.31,32
This G80A polymorphism is also in LD with SLC19A1
IVS5(9148)CA polymorphism (D’  0.949, r2  0.753,
LOD  12.64) whose AA genotype also predicted for OS,
p  0.03, in our study. This observation suggests that genetic
variations in SLC19A1 might predict for clinical outcome in
pemetrexed therapy. Smit et al.33 recently reported that there
was no association between the SLC19A1 G80A SNP and
PFS for patients on pemetrexed-carboplatin versus pem-
etrexed. In this study, it is the wild-type CC genotype of
SLC19A1 exon6 (2522) that demonstrated a trend toward a
longer PFS, an observation also seen in a previous pem-
etrexed-bevacizumab combination therapy study,30 suggest-
ing that studies with larger patient cohorts are necessary.
The variant C allele in GGH IVS2(1042)T C was
associated with increased CB and response in this study,
and it had also shown to be beneficial for decreased grade
4 AE in another study involving pemetrexed.30 This sug-
gests that the GGH INV2(1042)TC polymorphism also
plays a role in pemetrexed treatment outcome. We were
not able to analyze these tag SNPs to assess their role in
the differences in response rates between the different
regimens because of small sample numbers. Therefore, we
are unable to report whether a specific regimen might have
influenced an association with the tag SNPs. However, all
the polymorphisms that were associated with efficacy or
toxicity of pemetrexed had allele frequencies that were
relatively common; FPGS (8%), GGH (11–26%), and
SLC19A1 (42–56%), suggesting that inherited genetic vari-
ants, particularly for SLC19A1, could potentially contrib-
ute to clinical outcome after pemetrexed therapy, in a large
proportion of the population.
In summary, our preliminary observations suggest that
germ-line polymorphisms in FPGS and GGH are important
determinants of pemetrexed response and toxicity, whereas
polymorphisms in SLC19A1 seem to predict for OS differ-
ences. Because this study had a small sample size, these
hypotheses-generating findings are being verified in an on-
going larger patient (n 1000) observational study of single-
agent pemetrexed.
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